Title :

Bicuspid aortic valve stenosis favorable early outcomes with a next-generation transcatheter heart valve in a multicenter study

Author(s) :

Perlman, Gidon Y. [Auteur]
Blanke, Philipp [Auteur]
Dvir, Danny [Auteur]
Pache, Gregor [Auteur]
Modine, Thomas [Auteur]
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Troubles cognitifs dégénératifs et vasculaires - U1171
Barbanti, Marco [Auteur]
Holy, Erik W. [Auteur]
Treede, Hendrik [Auteur]
Ruile, Philipp [Auteur]
Neumann, Franz-Josef [Auteur]
Gandolfo, Caterina [Auteur]
Saia, Francesco [Auteur]
Tamburino, Corrado [Auteur]
Mak, George [Auteur]
Thompson, Christopher [Auteur]
Wood, David [Auteur]
Leipsic, Jonathon [Auteur]
Webb, John G. [Auteur]

Journal title :

JACC. Cardiovascular interventions

Abbreviated title :

JACC-Cardiovasc. Interv.

Volume number :

9

Pages :

817-824

Publication date :

2016-04-25

ISSN :

1936-8798

English keyword(s) :

aortic stenosis
bicuspid
transcatheter aortic valve replacement

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

OBJECTIVE: This study evaluated the results of transcatheter aortic valve replacement (TAVR) in bicuspid aortic stenosis (AS) using a new-generation TAVR device. BACKGROUND: A bicuspid AS is often considered a relative ...
Show more >OBJECTIVE: This study evaluated the results of transcatheter aortic valve replacement (TAVR) in bicuspid aortic stenosis (AS) using a new-generation TAVR device. BACKGROUND: A bicuspid AS is often considered a relative contraindication to TAVR. Although initial reports have demonstrated feasibility using early-generation devices, outcomes have not matched those seen with tricuspid AS. Paravalvular aortic regurgitation (AR) has been particularly problematic. METHODS: We collected baseline characteristics, procedural data, and 30-day clinical follow-up findings from 8 centers in Europe and Canada that had performed TAVR in bicuspid AS using the SAPIEN 3 valve. RESULTS: 51 patients underwent TAVR using the SAPIEN 3 valve. Patient mean age was 76.2 ± 9.3 years and the Society of Thoracic Surgeons predicted risk of mortality scores were 5.2 ± 3.7%. Bicuspid valve types were: type 0, 11.8%; type 1, 82.3%; and type 2, 1.9%. There were no cases of valve embolization or need for a second valve. Post-dilation was performed in 7.8%. The mean aortic gradient decreased from 49.4 ± 16.0 mm Hg to 11.2 ± 4.7 mm Hg. Post-implantation AR was none/trivial in 63% and mild in 37%. There were no cases of moderate or severe AR. At 30-day follow-up, there were 2 deaths (3.9%), 2 major vascular complications, and 12 patients (23.5%) required pacemaker implantation. CONCLUSIONS: TAVR in bicuspid AS using a new-generation device was feasible and effective with favorable valve performance and no cases of moderate or severe AR.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
CNRS
Inserm
Université de Lille

Collections :

• Lille Neurosciences & Cognition (LilNCog) - U 1172

Research team(s) :

Troubles cognitifs dégénératifs et vasculaires

Submission date :

2019-11-27T14:29:15Z